OMER Latest Press Releases

-- March 31, 2026 --

Omeros Corporation Reports Fourth Quarter and Year-End 2025 Financial Results Business Wire 4:02 PM

-- March 26, 2026 --

Omeros Corporation to Announce Fourth Quarter and Full-Year 2025 Financial Results on March 31, 2026 Business Wire 8:45 AM

-- March 21, 2026 --

Omeros Announces Upcoming Presentation at EBMT 2026 Highlighting Advances in TA-TMA Treatment Business Wire 3:23 AM

-- February 17, 2026 --

Omeros Announces Successful Primate Study in OncotoX-AML Drug Program Business Wire 8:45 AM

-- January 27, 2026 --

Omeros Announces First Commercial Sales of YARTEMLEA Business Wire 9:00 AM

-- December 26, 2025 --

Omeros Announces New Date for YARTEMLEA Approval Conference Call Business Wire 6:36 PM

-- December 24, 2025 --

FDA Approves Omeros' YARTEMLEA - First and Only Therapy Indicated for TA-TMA Business Wire 9:00 AM

-- December 1, 2025 --

Omeros Corporation Announces Closing of Asset Purchase and License Agreement with Novo Nordisk for Omeros' Clinical-Stage MASP-3 Inhibitor Zaltenibart (OMS906) Business Wire 8:30 AM

-- November 13, 2025 --

Omeros Corporation Reports Third Quarter 2025 Financial Results Business Wire 4:11 PM

-- November 11, 2025 --

Omeros Corporation to Announce Third Quarter Financial Results on November 13, 2025 Business Wire 8:30 AM

Market Data Delayed 15 Minutes

Questions? Feedback?Olark live chat software